BioCentury
ARTICLE | Company News

Amgen still head of class in CGRP-migraine

July 31, 2019 12:44 AM UTC

As Amgen and Lilly continue to expand their presence in the migraine prevention market, the former's first-in-class CGRP inhibitor is maintaining its lead in the space.

Amgen Inc. (NASDAQ:AMGN) and Eli Lilly and Co. (NYSE:LLY) reported 2Q19 sales of their calcitonin-related gene peptide (CGRP) inhibitors to treat migraine Tuesday. Aimovig erenumab-aooe generated $83 million in sales for the quarter, up 41% from 1Q19 and beating analyst expectations of $75.2 million...